ESPR vs. AQST
ESPR (Esperion Therapeutics, Inc.) and AQST (Aquestive Therapeutics, Inc.) are both stocks. Both are in the Healthcare sector — ESPR in Biotechnology, AQST in Drug Manufacturers - Specialty & Generic. Over the past 5 years, ESPR returned -29.19%/yr vs 2.60%/yr for AQST. Their 0.21 correlation means their historical movements had little consistent relationship.
Performance
ESPR vs. AQST - Performance Comparison
Loading charts...
Returns By Period
In the year-to-date period, ESPR achieves a -14.05% return, which is significantly higher than AQST's -42.80% return.
ESPR
- 1D
- 0.00%
- 1M
- 0.63%
- 6M
- -6.19%
- YTD
- -14.05%
- 1Y
- 127.14%
- 3Y*
- 30.22%
- 5Y*
- -29.19%
- 10Y*
- -11.79%
- ALL TIME*
- -12.06%
AQST
- 1D
- -0.67%
- 1M
- -11.60%
- 6M
- 25.25%
- YTD
- -42.80%
- 1Y
- -3.27%
- 3Y*
- 18.16%
- 5Y*
- 2.60%
- 10Y*
- —
- ALL TIME*
- -16.07%
Liquidity Comparison
| Position | Avg. Volume Value (2W) | Avg. Volume Value (1M) | Avg. Volume Value (3M) |
|---|---|---|---|
| $7.65M | $7.26M | $8.26M |
ESPR vs. AQST - Yearly Performance Comparison
| 2026 (YTD) | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|---|---|---|---|
ESPR Esperion Therapeutics, Inc. | -14.05% | 68.18% | -26.42% | -52.01% | 24.60% | -80.77% | -56.40% | 29.63% | 6.78% |
AQST Aquestive Therapeutics, Inc. | -42.80% | 81.46% | 76.24% | 123.92% | -76.81% | -27.29% | -8.08% | -7.62% | -58.14% |
Correlation
The correlation between ESPR and AQST is 0.26, which is low. Their historical price movements had little consistent relationship.
| Correlation | |
|---|---|
Correlation (1Y) Focuses on recent behavior, but can change the most. | 0.26 |
Correlation (3Y) Balances recent behavior with more history. | 0.24 |
Correlation (5Y) Shows whether the relationship held over a longer period. | 0.22 |
Correlation (All Time) Calculated using the full available price history since Jul 25, 2018 | 0.21 |
Fundamentals
ESPR:
$661.15M
AQST:
$463.60M
ESPR:
-$0.03
AQST:
-$0.58
ESPR:
1.86
AQST:
8.70
ESPR:
$418.24M
AQST:
$50.27M
ESPR:
$226.32M
AQST:
$20.92M
ESPR:
$77.18M
AQST:
-$53.08M
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Return for Risk
ESPR vs. AQST — Risk / Return Rank
ESPR
Risk / return metrics aren't available yet — we need at least 12 months of trading data to calculate them.
AQST
ESPR vs. AQST - Risk-Adjusted Trends Comparison
This table presents a comparison of risk-adjusted performance metrics for Esperion Therapeutics, Inc. (ESPR) and Aquestive Therapeutics, Inc. (AQST). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.
| ESPR | AQST | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | +1.91 | ||
| Sortino ratioReturn per unit of downside risk | +2.36 | ||
| Omega ratioGain probability vs. loss probability | 1.39 | 1.09 | +0.30 |
| Calmar ratioReturn relative to maximum drawdown | 3.16 | -0.06 | +3.23 |
| Martin ratioReturn relative to average drawdown | 7.64 | -0.11 | +7.75 |
Loading charts...
Drawdowns
ESPR vs. AQST - Drawdown Comparison
The maximum ESPR drawdown since its inception was -99.37%, roughly equal to the maximum AQST drawdown of -96.68%. Use the drawdown chart below to compare losses from any high point for ESPR and AQST.
Loading charts...
Drawdown Indicators
| ESPR | AQST | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -99.37% | -96.68% | -2.69% |
Max Drawdown (1Y)Largest decline over 1 year | -53.19% | -60.61% | +7.42% |
Max Drawdown (3Y)Largest decline over 3 years | -80.94% | -63.55% | -17.39% |
Max Drawdown (5Y)Largest decline over 5 years | -95.13% | -90.11% | -5.02% |
Max Drawdown (10Y)Largest decline over 10 years | -99.10% | — | — |
Current DrawdownCurrent decline from peak | -97.24% | -80.51% | -16.73% |
Average DrawdownAverage peak-to-trough decline | -70.15% | -76.94% | +6.79% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 21.98% | 35.71% | -13.73% |
Volatility
ESPR vs. AQST - Volatility Comparison
The current volatility for Esperion Therapeutics, Inc. (ESPR) is 1.75%, while Aquestive Therapeutics, Inc. (AQST) has a volatility of 11.54%. This indicates that ESPR experiences smaller price fluctuations and is considered to be less risky than AQST based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Loading charts...
Volatility by Period
| ESPR | AQST | Difference | |
|---|---|---|---|
Volatility (1M)Calculated over the trailing 1-month period | 1.75% | 11.54% | -9.79% |
Volatility (6M)Calculated over the trailing 6-month period | 59.70% | 49.75% | +9.95% |
Volatility (1Y)Calculated over the trailing 1-year period | 90.39% | 84.71% | +5.68% |
Volatility (5Y)Calculated over the trailing 5-year period, annualized | 91.65% | 82.60% | +9.05% |
Volatility (10Y)Calculated over the trailing 10-year period, annualized | 83.40% | 87.24% | -3.84% |
Dividends
ESPR vs. AQST - Dividend Comparison
Neither ESPR nor AQST has paid dividends to shareholders.
Financials
ESPR vs. AQST - Financials Comparison
This section allows you to compare key financial metrics between Esperion Therapeutics, Inc. and Aquestive Therapeutics, Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.
Total Revenue: Total amount of money received from sales and other business activities
ESPR vs. AQST - Profitability Comparison
ESPR - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on Aug 2026, Esperion Therapeutics, Inc. reported a gross profit of 0.00 and revenue of 80.10M. Therefore, the gross margin over that period was 0.0%.
AQST - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on Aug 2026, Aquestive Therapeutics, Inc. reported a gross profit of 0.00 and revenue of 14.45M. Therefore, the gross margin over that period was 0.0%.
ESPR - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on Aug 2026, Esperion Therapeutics, Inc. reported an operating income of -6.58M and revenue of 80.10M, resulting in an operating margin of -8.2%.
AQST - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on Aug 2026, Aquestive Therapeutics, Inc. reported an operating income of -4.20M and revenue of 14.45M, resulting in an operating margin of -29.1%.
ESPR - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on Aug 2026, Esperion Therapeutics, Inc. reported a net income of -25.20M and revenue of 80.10M, resulting in a net margin of -31.5%.
AQST - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on Aug 2026, Aquestive Therapeutics, Inc. reported a net income of -8.06M and revenue of 14.45M, resulting in a net margin of -55.8%.
Frequently Asked Questions
ESPR and AQST have a correlation of 0.26, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.
AQST has higher volatility (11.54%) compared to ESPR (1.75%). In terms of maximum drawdown, ESPR dropped -99.37% vs AQST's -96.68%.
ESPR currently has the higher Sharpe Ratio (1.87 vs -0.04), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.
Find the right allocation for ESPR and AQST
Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Optimizer